Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL‐1
- 5 March 2021
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 16 (11) , 1789-1798
Abstract
Drimane sesquiterpenoid dialdehydes are natural compounds with antiproliferative properties. Nevertheless, their mode of action has not yet been discovered. Herein, we demonstrate that various drimanes are potent inhibitors of MCL‐1 and BCL‐xL, two proteins of the BCL‐2 family that are overexpressed in various cancers, including lymphoid malignancies. Subtle changes in their structure significantly modified their activity on the target proteins. The two most active compounds are MCL‐1 selective and bind in the BH3 binding groove of the protein. Complementary studies by NMR spectroscopy and mass spectrometry analyses, but also synthesis, showed that they covalently inhibit MCL‐1 though the formation of a pyrrole adduct. In addition, cytotoxic assays revealed that these two compounds show a cytotoxic selectivity for BL2, a MCL‐1/BCL‐xL‐dependent cell line and induce apoptosis.Keywords
Funding Information
- Agence Nationale de la Recherche (ANR-10-LABX-25-01, IR-RMN-THC FR 3050 CNRS)
This publication has 50 references indexed in Scilit:
- Pan-cancer patterns of somatic copy number alterationNature Genetics, 2013
- Ophiobolin A induces paraptosis-like cell death in human glioblastoma cells by decreasing BKCa channel activityCell Death & Disease, 2013
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in CancerJournal of Clinical Oncology, 2012
- Deciphering the rules of programmed cell death to improve therapy of cancer and other diseasesThe EMBO Journal, 2011
- Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistanceBlood, 2010
- Apoptotic Regulation by MCL-1 through HeterodimerizationJournal of Biological Chemistry, 2010
- A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapyCell Death & Disease, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Bcl-2–family proteins and hematologic malignancies: history and future prospectsBlood, 2008
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973